DASI Simulations, OH-based company gained FDA clearance for an artificial intelligence (AI) Product that identifies and measures cardiac structures in CT scans
Reporter: Aviva Lev-Ari, PhD, RN
DASI Simulations previously gained FDA approval for PrecisionTAVI, an advanced AI model capable of predicting certain patient outcomes before patients undergo TAVR.
The company’s DASI Dimensions platform was developed to help care teams plan ahead of transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The cloud-based software was developed in the research lab of the company’s founder and chief technology officer, Lakshmi Prasad Dasi, PhD, a bioengineer with Georgia Tech University.
DASI Simulations previously gained FDA approval for PrecisionTAVI, an advanced AI model capable of predicting certain patient outcomes before patients undergo TAVR.
“Our mission—to provide an AI-powered structural heart platform that allows physicians to be more efficient and use their expertise more effectively—is moving forward with great momentum,” Teri Sirset, founder and CEO of DASI Simulations, said in a statement.
The DASI Dimensions approval is just the latest example of cardiology’s role as a significant leader in the development and use of healthcare AI. Cardiology ranks No. 2 among all specialties when it comes to cleared AI algorithms, trailing only radiology.
The Landscape of other players in AI and Medical Imaging
Siemens Healthineers, Nanox.AI and AISAP have all gained key FDA clearances/approvals since Aug. 1, suggesting this trend is not slowing down anytime soon. The FDA even named a cardiologist—digital health specialist Ami B. Bhatt, MD—as the first chair of its new Digital Health Advisory Committee, highlighting the prominent roles cardiologists are having in AI-related conversations on a regular basis.
Cardiovascular Surgeon
Piedmont Heart Valve Society
2012pharmaceutical
sjwilliamspa
Leave a Reply